BioLineRx (BLRX) Other Gross PP&E Adjustments (2019 - 2025)
BioLineRx (BLRX) posted Other Gross PP&E Adjustments of -$696000.0 for Q4 2025, up 3.87% on a QoQ basis from -$724000.0 in Q3 2025, and up 28.02% year-over-year from -$543644.6 in Q4 2024.
BioLineRx (BLRX) has 7 years of Other Gross PP&E Adjustments data on file, last reported at -$696000.0 in Q4 2025.
- In Q4 2025, Other Gross PP&E Adjustments rose 28.02% year-over-year to -$696000.0; the TTM figure through Dec 2025 stood at -$696000.0 (up 28.02% YoY), while the FY2025 annual figure was -$696000.0, up 28.02% from the prior year.
- Other Gross PP&E Adjustments climbed to -$696000.0 in Q4 2025, from -$724000.0 in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$696000.0 in Q4 2025 and bottomed at -$1.8 million in Q4 2022.
- A 5-year average of -$1.3 million and a median of -$1.3 million in 2021 frame the typical range for Other Gross PP&E Adjustments.
- Annual changes were most pronounced in 2022 — Other Gross PP&E Adjustments tumbled 33.13% — and 2025, when it jumped 48.21%.
- Year by year, Other Gross PP&E Adjustments stood at -$1.3 million in 2021, then plunged by 33.13% to -$1.8 million in 2022, then gained by 20.15% to -$1.4 million in 2023, then soared by 31.66% to -$967000.0 in 2024, then gained by 28.02% to -$696000.0 in 2025.
- The last three Other Gross PP&E Adjustments figures came in at -$696000.0 (Q4 2025), -$724000.0 (Q3 2025), and -$800000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -189.30 Mn |
| 10 | BioLineRx | 9.32 Bn | 9.30 Bn | 154,000.00 | -696,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -696,000.00 |
| Dec 31, 2025 | -696,000.00 |
| Sep 30, 2025 | -724,000.00 |
| Sep 30, 2025 | -724,000.00 |
| Jun 30, 2025 | -800,000.00 |
| Jun 30, 2025 | -800,000.00 |
| Mar 31, 2025 | -863,000.00 |
| Mar 31, 2025 | -863,000.00 |
| Dec 31, 2024 | -967,000.00 |
| Dec 31, 2024 | -967,000.00 |
| Sep 30, 2024 | -1.40 Mn |
| Sep 30, 2024 | -1.40 Mn |
| Jun 30, 2024 | -1.45 Mn |
| Jun 30, 2024 | -1.45 Mn |
| Mar 31, 2024 | -1.31 Mn |
| Mar 31, 2024 | -1.31 Mn |
| Dec 31, 2023 | -1.42 Mn |
| Dec 31, 2023 | -1.42 Mn |
| Sep 30, 2023 | -1.46 Mn |
| Sep 30, 2023 | -1.46 Mn |
| Jun 30, 2023 | -1.58 Mn |
| Jun 30, 2023 | -1.58 Mn |
| Mar 31, 2023 | -1.69 Mn |
| Mar 31, 2023 | -1.69 Mn |
| Dec 31, 2022 | -1.77 Mn |
| Dec 31, 2022 | -1.77 Mn |
| Sep 30, 2022 | -1.29 Mn |
| Sep 30, 2022 | -1.29 Mn |
| Jun 30, 2022 | -1.22 Mn |
| Jun 30, 2022 | -1.22 Mn |
| Mar 31, 2022 | -1.27 Mn |
| Mar 31, 2022 | -1.27 Mn |
| Dec 31, 2021 | -1.33 Mn |
| Dec 31, 2021 | -1.33 Mn |
| Sep 30, 2021 | -1.34 Mn |
| Sep 30, 2021 | -1.34 Mn |
| Jun 30, 2021 | -1.42 Mn |
| Jun 30, 2021 | -1.42 Mn |
| Mar 31, 2021 | -1.30 Mn |
| Mar 31, 2021 | -1.30 Mn |
| Dec 31, 2020 | -1.36 Mn |
| Dec 31, 2020 | -1.36 Mn |
| Sep 30, 2020 | -1.42 Mn |
| Sep 30, 2020 | -1.42 Mn |
| Jun 30, 2020 | -1.49 Mn |
| Jun 30, 2020 | -1.49 Mn |
| Mar 31, 2020 | -1.57 Mn |
| Mar 31, 2020 | -1.57 Mn |
| Dec 31, 2019 | -1.65 Mn |
| Dec 31, 2019 | -1.65 Mn |
| Sep 30, 2019 | -1.64 Mn |
| Sep 30, 2019 | -1.64 Mn |
| Jun 30, 2019 | -1.72 Mn |
| Jun 30, 2019 | -1.72 Mn |
| Mar 31, 2019 | -1.80 Mn |
| Mar 31, 2019 | -1.80 Mn |